Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This review analyzes the ACEL-UK-ETT emulated target trial, demonstrating that long-term levothyroxine therapy in older adults with subclinical hypothyroidism significantly reduces cardiovascular events and all-cause mortality without compr
A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populat
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
This review synthesizes findings from the GALACTIC-HF trial regarding the efficacy and safety of omecamtiv mecarbil across age groups, highlighting its benefits in older patients and those with severe heart failure.
Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.